Skip to main content

Table 1 Demographics and neuropsychological assessments for all CN participants

From: Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study

 

CN− (n = 34)

CN+ (n = 32)

P value

Demographic information

 Age (years)

66.91 ± 5.28

68.44 ± 5.35

0.507

 Sex (M/F)

8/26

10/22

0.482

 Education (years)

12.76 ± 2.99

12.69 ± 2.62

0.901

 BMI

23.78 ± 2.90

24.42 ± 2.74

0.287

 APOE ε4 (%)

11 (32.35%)

12 (37.50%)

0.661

 Diabetes (%)

5 (14.71%)

1(3.13%)

0.102

 Hypertension (%)

15 (44.12%)

12 (37.50%)

0.585

Neuropsychological tests

 HAMD

2.88 ± 3.51

3.81 ± 3.83

0.199

 HAMA

3.44 ± 3.26

3.75 ± 2.65

0.407

 MoCA-B

25.76 ± 2.73

26.28 ± 2.76

0.385

 AVLT-D (long)

8.74 ± 1.66

7.75 ± 1.88

0.018*

 AVLT-R

22.94 ± 1.13

22.63 ± 1.62

0.489

 STT-A

51.47 ± 15.72

62.53 ± 24.66

0.088

 STT-B

121.09 ± 32.60

142.22 ± 47.95

0.039*

 AFT

18.74 ± 4.59

19.91 ± 3.95

0.272

 BNT

25.65 ± 2.86

26.25 ± 2.66

0.342

 FAQ

1.00 ± 1.72

0.97 ± 1.12

0.333

  1. Abbreviations: CN− amyloid-β-negative cognitively normal participants, CN+ amyloid-β-positive cognitively normal participants, M male, F female, BMI body mass index, APOE apolipoprotein E, HAMD Hamilton Depression Rating Scale, HAMA Hamilton Anxiety Rating Scale, MoCA-B Montreal Cognitive Assessment-Basic version, AVLT-D (long) Auditory Verbal Learning Test-long delayed recall, AVLT-R Auditory Verbal Learning Test-recognition, STT-A Shape Trails Test Part A, STT-B Shape Trails Test Part B, AFT Animal Fluency Test, BNT Boston Naming Test, FAQ Functional Activities Questionnaire
  2. *P < 0.05, comparison between CN− and CN+